251 related articles for article (PubMed ID: 23747486)
21. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.
Mitsani D; Nguyen MH; Shields RK; Toyoda Y; Kwak EJ; Silveira FP; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Clancy CJ
Antimicrob Agents Chemother; 2012 May; 56(5):2371-7. PubMed ID: 22330924
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).
Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN
Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of voriconazole in children.
Chen J; Chan C; Colantonio D; Seto W
Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
[TBL] [Abstract][Full Text] [Related]
24. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
25. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the effect of obesity on voriconazole serum concentrations.
Koselke E; Kraft S; Smith J; Nagel J
J Antimicrob Chemother; 2012 Dec; 67(12):2957-62. PubMed ID: 22915462
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
28. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
[TBL] [Abstract][Full Text] [Related]
29. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
31. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
Hamada Y; Seto Y; Yago K; Kuroyama M
J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.
Carbonara S; Regazzi M; Ciracì E; Villani P; Stano F; Cusato M; Heichen M; Monno L
Ann Pharmacother; 2009 May; 43(5):978-84. PubMed ID: 19383934
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
34. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
35. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole hepatotoxicity in severe liver dysfunction.
Solís-Muñoz P; López JC; Bernal W; Willars C; Verma A; Heneghan MA; Wendon J; Auzinger G
J Infect; 2013 Jan; 66(1):80-6. PubMed ID: 23041040
[TBL] [Abstract][Full Text] [Related]
37. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
39. Pharmacology and clinical use of voriconazole.
Thompson GR; Lewis JS
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
[TBL] [Abstract][Full Text] [Related]
40. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.
Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ
Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
